Novavax Framtida tillväxt
Future kriterier kontrolleras 3/6
Novavax s intäkter förväntas minska med 5.8% per år medan dess årliga intäkter förväntas växa med 60.6% per år. EPS förväntas tillväxt med 60.7% per år.
Viktig information
60.6%
Tillväxttakt i vinsten
60.72%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 24.8% |
| Intäkternas tillväxttakt | -5.8% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 12 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jun 02
NVAX: Bearish View Will Hinge On Sustained COVID Vaccine Demand Beyond XFG Update
Analysts have lifted their Novavax price target to $9 from $8, citing updated assumptions around slower revenue declines, higher profit margins, and a lower future P/E multiple as key drivers of the change. Analyst Commentary Recent research points to a more cautious tone around Novavax, even as price targets are adjusted.Seeking Alpha • May 30
Novavax: The Pivot To A Royalty Model Is Working, But It's Still A Hold
Summary Novavax maintains a Hold rating as it transitions to a royalty-driven model, with shrinking direct product sales and a focus on partner revenue. NVAX's COVID-19/flu vaccine partnership with Sanofi is operationally ready, but the seasonal COVID-19 market remains niche and unlikely to drive significant upside. Q1 2026 revenue was $140 million, with guidance reaffirmed at $230–$270 million for the year, mostly from royalties; cash runway extends into 2028. Pipeline catalysts, including C. diff vaccine progress and milestone inflows, are largely priced in; meaningful upside requires clinical and financial differentiation. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 26
NVAX: Bearish View Will Hinge On Sustained COVID Vaccination Demand
Analysts have raised their blended price targets for Novavax by about $1 per share to a range of around $7 to $8, citing updated assumptions for COVID demand, refreshed 2026 revenue and expense forecasts, and the contribution from recent partnership agreements. Analyst Commentary Recent Street research around Novavax reflects a mix of caution and tempered expectations, even as price targets move slightly higher into the mid single digit range.Uppdatering av berättelse • Apr 11
NVAX: Bearish View Will Hinge On Future COVID Demand Execution
Analysts have modestly lifted their average price targets on Novavax shares, with several moving from the $6 to $7 range toward $8 as they update COVID demand assumptions and incorporate new guidance on future revenue, operating expenses, and licensing income. Analyst Commentary Recent Street research on Novavax reflects a cautious tone, even as some targets edge higher.Uppdatering av berättelse • Mar 28
NVAX: Bearish Outlook Will Depend On Pfizer Royalty And COVID Demand Assumptions
Novavax's average analyst price target has edged higher by about $1, as analysts refine their COVID assumptions, update revenue and expense forecasts for future years, and factor recent partnership economics into their models. Analyst Commentary Recent Street research around Novavax points to a cautious tone, even as price targets move slightly higher.Uppdatering av berättelse • Mar 14
NVAX: Cautious Outlook Will Hinge On Future Pfizer Royalty Execution
Narrative Update on Novavax The analyst price target for Novavax has increased by about $1 to a new consensus of $7, as analysts adjust their models for updated COVID demand assumptions, refreshed 2026 revenue and expense forecasts, and the impact of recent partnership and licensing agreements. Analyst Commentary Recent Street research on Novavax points to a mixed but generally cautious stance.
Uppdatering av berättelse • Feb 27
NVAX: Licensing And Royalty Streams Will Drive Future Cash Generation
Analysts have lifted their average price target on Novavax to about $13.78 from roughly $13.11, citing updated COVID demand assumptions, refreshed revenue and expense forecasts, and revised P/E expectations that incorporate recent guidance and licensing agreements. Analyst Commentary Recent Street research reflects a mix of cautious optimism and ongoing concern, with several firms adjusting their price targets and underlying models around Novavax's COVID franchise, expense profile, and licensing income.Analysartikel • Jan 14
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 32% in the last...Uppdatering av berättelse • Nov 08
NVAX: Shifting To Licensing Will Drive Royalties And Upfront Payments
Novavax's analyst price target has been modestly reduced from $13.21 to $13.11 per share. This change reflects analysts' cautious optimism about the company's new licensing model, expected royalties, and commercial partnership opportunities.Uppdatering av berättelse • Oct 24
Confidence In Licensing Shift And Partnerships Will Drive Opportunities Ahead
The analyst price target for Novavax has been raised from $12.50 to $13.21. This reflects analyst confidence in the company’s transition to a licensing model as well as opportunities for revenue from new partnerships and technology platforms.Uppdatering av berättelse • Sep 04
Global Vaccine Market Will Unlock Upside Despite Execution Risks
Novavax’s consensus price target was modestly reduced, primarily due to a slight decline in its future P/E ratio, bringing fair value down from $12.86 to $12.50. What's in the News Reports indicate that the Trump administration and Robert F.Analysartikel • May 20
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...Seeking Alpha • Apr 28
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Summary Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves, yet uncertainties in its COVID-19 vaccine remain. NVAX stock's rating maintained at "Hold" despite ongoing hurdles based on improved cash position and potential future opportunities. Investors should remain cautious, balancing optimism with awareness of persistent risks and market volatility. Read the full article on Seeking Alpha
Ny berättelse • Apr 22
Sanofi Partnership And Pipeline Programs Will Expand Future Markets
Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.Seeking Alpha • Apr 11
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Summary Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that single-antigen vaccines don't work for respiratory diseases caused Novavax stock to plummet 20%. FDA approval delay for Nuvaxovid jeopardizes a crucial $175M milestone payment, though Novavax has the financial flexibility to survive this setback. Despite significant regulatory and competitive risks, NVAX stock maintains a "Hold" rating as a speculative component for barbell portfolios. Read the full article on Seeking AlphaAnalysartikel • Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%
Novavax, Inc. ( NASDAQ:NVAX ) shareholders that were waiting for something to happen have been dealt a blow with a 28...Analysartikel • Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Novavax, Inc. ( NASDAQ:NVAX ) shareholders, with the analysts delivering a substantial...Seeking Alpha • Jan 16
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Summary I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. The partnership with Sanofi offers significant benefits but does not assure it of ongoing success. My analysis remains cautious, emphasizing the need for careful consideration of Novavax's long-term viability and strategic moves. Read the full article on Seeking AlphaAnalysartikel • Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...Analysartikel • Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Novavax, Inc. ( NASDAQ:NVAX ) defied analyst predictions to release its third-quarter results, which were ahead of...Seeking Alpha • Nov 13
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Summary Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines. Despite effective products, reduced guidance and restructuring uncertainty make NVAX stock a hold, with the Sanofi partnership and upcoming milestones as a potential bullish catalyst. Read the full article on Seeking AlphaAnalysartikel • Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Novavax, Inc. ( NASDAQ:NVAX ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Oct 31
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Summary Novavax' Q3 earnings are due on 6th November. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine. Novavax succeeded, but Nuvaxovid came to the market too late to build market share and the company ended up making heavy losses. Sanofi has acquired the rights to nuvaxovid, paying Novavax $500m upfront, and will look to develop a COVID / Influenza combo vaccine using Novavax' technology. Unfortunately, Sanofi milestones and revenues aside, that leaves Novavax with few opportunities to generate revenue, which likely means its valuation will fall over time. Read the full article on Seeking AlphaSeeking Alpha • Sep 01
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Summary Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.1 variant, but newer Omicron variants have outpaced it, limiting competitive advantage. Financial stability hinges on achieving key milestones in the Sanofi partnership and successful commercialization of new vaccines. Despite the Sanofi deal, maintaining a "hold" position is prudent given the high-risk nature of Novavax's future prospects. Read the full article on Seeking AlphaAnalysartikel • Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Novavax, Inc.'s ( NASDAQ:NVAX ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now...Seeking Alpha • Aug 13
Novavax: Staying Long Despite Coming Up Short In Q2
Summary Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi partnership, and potential market opportunities, despite disappointing Q2 earnings. I provide my thoughts on the quarter, and will highlight a few downside risks that investors should consider. I discuss my updated NVAX strategy. Read the full article on Seeking AlphaPrognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 362 | 83 | 171 | 18 | 6 |
| 12/31/2027 | 258 | -43 | -20 | -132 | 9 |
| 12/31/2026 | 410 | -79 | -211 | -269 | 9 |
| 3/31/2026 | 596 | -88 | -98 | -92 | N/A |
| 12/31/2025 | 1,123 | 440 | -251 | -245 | N/A |
| 9/30/2025 | 1,065 | 342 | -385 | -378 | N/A |
| 6/30/2025 | 1,079 | 423 | -637 | -631 | N/A |
| 3/31/2025 | 1,255 | 479 | -198 | -189 | N/A |
| 12/31/2024 | 682 | -187 | -102 | -87 | N/A |
| 9/30/2024 | 885 | -285 | -112 | -91 | N/A |
| 6/30/2024 | 988 | -294 | -24 | 14 | N/A |
| 3/31/2024 | 997 | -399 | -514 | -472 | N/A |
| 12/31/2023 | 984 | -545 | -773 | -714 | N/A |
| 9/30/2023 | 1,050 | -549 | -727 | -655 | N/A |
| 6/30/2023 | 1,597 | -587 | -737 | -654 | N/A |
| 3/31/2023 | 1,359 | -1,155 | -753 | -653 | N/A |
| 12/31/2022 | 1,982 | -658 | -509 | -416 | N/A |
| 9/30/2022 | 1,847 | -1,322 | -728 | -641 | N/A |
| 6/30/2022 | 1,291 | -1,476 | -814 | -744 | N/A |
| 3/31/2022 | 1,403 | -1,318 | -489 | -429 | N/A |
| 12/31/2021 | 1,146 | -1,744 | 265 | 323 | N/A |
| 9/30/2021 | 1,204 | -1,075 | 454 | 537 | N/A |
| 6/30/2021 | 1,182 | -950 | 593 | 672 | N/A |
| 3/31/2021 | 919 | -615 | 575 | 644 | N/A |
| 12/31/2020 | 476 | -418 | -97 | -43 | N/A |
| 9/30/2020 | 205 | -273 | 49 | 62 | N/A |
| 6/30/2020 | 50 | -93 | 32 | 37 | N/A |
| 3/31/2020 | 18 | -115 | -110 | -109 | N/A |
| 12/31/2019 | 19 | -133 | N/A | -137 | N/A |
| 9/30/2019 | 16 | -150 | N/A | -158 | N/A |
| 6/30/2019 | 21 | -177 | N/A | -159 | N/A |
| 3/31/2019 | 29 | -182 | N/A | -169 | N/A |
| 12/31/2018 | 34 | -185 | N/A | -185 | N/A |
| 9/30/2018 | 39 | -186 | N/A | -183 | N/A |
| 6/30/2018 | 39 | -186 | N/A | -194 | N/A |
| 3/31/2018 | 35 | -186 | N/A | -166 | N/A |
| 12/31/2017 | 31 | -184 | N/A | -144 | N/A |
| 9/30/2017 | 26 | -190 | N/A | -162 | N/A |
| 6/30/2017 | 21 | -212 | N/A | -181 | N/A |
| 3/31/2017 | 17 | -247 | N/A | -230 | N/A |
| 12/31/2016 | 15 | -280 | N/A | -259 | N/A |
| 9/30/2016 | 16 | -302 | N/A | -249 | N/A |
| 6/30/2016 | 19 | -269 | N/A | -215 | N/A |
| 3/31/2016 | 31 | -210 | N/A | -165 | N/A |
| 12/31/2015 | 36 | -157 | N/A | -126 | N/A |
| 9/30/2015 | 37 | -110 | N/A | -91 | N/A |
| 6/30/2015 | 39 | -96 | N/A | -78 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: NVAX förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.5% ).
Resultat vs marknad: NVAX förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.
Höga tillväxtresultat: NVAX förväntas bli lönsam under de kommande 3 åren.
Intäkt vs marknad: NVAX s intäkter förväntas minska under de kommande 3 åren ( -5.8% per år).
Hög tillväxtintäkter: NVAX s intäkter förväntas minska under de kommande 3 åren ( -5.8% per år).
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om NVAX s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/08 04:43 |
| Aktiekurs vid dagens slut | 2026/06/08 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Novavax, Inc. bevakas av 23 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital Historical (Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |